在临床前发现和开发的atogepant为偏头痛预防
Carlo Baraldi1, Dagmar Beier2,3,4, Paolo Martelletti5
1Azienda Unità Sanitaria Locale di Modena, Modena, Italy.
Expert opinion on drug discovery
|June 10, 2024
概括
阿托杰潘特通过阻断素基因相关 (CGRP) 受体提供了对偏头痛的新预防性治疗方法. 这种有针对性的方法有效地抑制疼痛通路,为偏头痛管理提供了有价值的选择.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛的病理生理学涉及与素基因相关的 (CGRP).
- 阿托基潘特是一种选择性CGRP受体对抗剂,用于偏头痛预防.
- 它抑制了Trigeminovascular nociception,解决了偏头痛的关键机制.
研究的目的:
- 审查Atogepant的开发,疗效,安全性和耐受性.
- 为了强调atogepant作为预防性偏头痛治疗的作用.
主要方法:
- 对同行评审文章进行全面的文献搜索.
- 对临床前数据,临床试验 (I-III阶段) 和监管批准的审查.
- 对疗效,安全性和耐受性数据的分析.
主要成果:
- 阿托杰潘特在预防偏头痛方面表现出临床疗效.
- 与早期的羊相比,它具有有利的安全概况,肝损伤风险降低.
- 药物相互作用研究需要更广泛的人口代表.
结论:
- 亚托杰潘特代表了在偏头痛预防方面取得的重大进展.
- 其改进的安全性解决了先前治疗方法的局限性.
- 未来的研究应该专注于不同的人口统计数据,以实现概括性.
相关概念视频
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
519
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
519
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159
Pharmacovigilance
825
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
825


